JP5006032B2 - 軟組織疾患の放射線治療におけるトリウム−２２７の使用 - Google Patents

軟組織疾患の放射線治療におけるトリウム−２２７の使用 Download PDF

Info

Publication number
JP5006032B2
JP5006032B2 JP2006506137A JP2006506137A JP5006032B2 JP 5006032 B2 JP5006032 B2 JP 5006032B2 JP 2006506137 A JP2006506137 A JP 2006506137A JP 2006506137 A JP2006506137 A JP 2006506137A JP 5006032 B2 JP5006032 B2 JP 5006032B2
Authority
JP
Japan
Prior art keywords
thorium
soft tissue
kbq
radium
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006506137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523664A (ja
JP2006523664A5 (enExample
Inventor
ロイ ラルセン
オイビィン ブルランド
Original Assignee
アルゲッタ エイエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0308731.9A external-priority patent/GB0308731D0/en
Application filed by アルゲッタ エイエス filed Critical アルゲッタ エイエス
Publication of JP2006523664A publication Critical patent/JP2006523664A/ja
Publication of JP2006523664A5 publication Critical patent/JP2006523664A5/ja
Application granted granted Critical
Publication of JP5006032B2 publication Critical patent/JP5006032B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2006506137A 2003-04-15 2004-04-15 軟組織疾患の放射線治療におけるトリウム−２２７の使用 Expired - Lifetime JP5006032B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0308731.9A GB0308731D0 (en) 2003-04-15 2003-04-15 Method of radiotherapy
GB0308731.9 2003-04-15
PCT/GB2004/001654 WO2004091668A1 (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011265169A Division JP5468597B2 (ja) 2003-04-15 2011-12-02 軟組織疾患の放射線治療におけるトリウム−２２７を用いた医薬組成物、複合体及びその調製方法、並びにキット

Publications (3)

Publication Number Publication Date
JP2006523664A JP2006523664A (ja) 2006-10-19
JP2006523664A5 JP2006523664A5 (enExample) 2012-02-09
JP5006032B2 true JP5006032B2 (ja) 2012-08-22

Family

ID=35385222

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006506137A Expired - Lifetime JP5006032B2 (ja) 2003-04-15 2004-04-15 軟組織疾患の放射線治療におけるトリウム−２２７の使用
JP2011265169A Expired - Lifetime JP5468597B2 (ja) 2003-04-15 2011-12-02 軟組織疾患の放射線治療におけるトリウム−２２７を用いた医薬組成物、複合体及びその調製方法、並びにキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011265169A Expired - Lifetime JP5468597B2 (ja) 2003-04-15 2011-12-02 軟組織疾患の放射線治療におけるトリウム−２２７を用いた医薬組成物、複合体及びその調製方法、並びにキット

Country Status (18)

Country Link
EP (1) EP1617876B1 (enExample)
JP (2) JP5006032B2 (enExample)
KR (2) KR20060015507A (enExample)
CN (1) CN100586484C (enExample)
AU (1) AU2004229218B2 (enExample)
BR (1) BRPI0409387B8 (enExample)
CA (1) CA2522148C (enExample)
CY (1) CY1115407T1 (enExample)
DK (1) DK1617876T3 (enExample)
EA (1) EA008195B1 (enExample)
ES (1) ES2486845T3 (enExample)
IL (1) IL171148A (enExample)
MX (1) MXPA05010804A (enExample)
NO (1) NO332931B1 (enExample)
NZ (3) NZ543044A (enExample)
PL (1) PL1617876T3 (enExample)
PT (1) PT1617876E (enExample)
ZA (1) ZA200507983B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1617876T3 (pl) * 2003-04-15 2015-03-31 Algeta Asa Tor-227 do zastosowania w radioterapii choroby tkanek miękkich
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
WO2018109667A1 (en) 2016-12-15 2018-06-21 Nestec Sa Compositions and methods that modulate white blood cells or neutrophils in a companion animal
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015625A1 (en) * 1989-06-19 1990-12-27 Akzo N.V. RADIOIMMUNOTHERAPY USING α-PARTICLES EMISSION
CA2117775A1 (en) * 1992-04-13 1993-10-28 Roberta C. Cheng Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
CN1073860C (zh) * 1998-08-20 2001-10-31 中国核动力研究设计院 用于骨肿瘤治疗或诊断的放射性药物药盒的制备方法
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
AU4906901A (en) * 2000-02-25 2001-09-17 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
ITMI20022411A1 (it) * 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
PL1617876T3 (pl) * 2003-04-15 2015-03-31 Algeta Asa Tor-227 do zastosowania w radioterapii choroby tkanek miękkich

Also Published As

Publication number Publication date
ZA200507983B (en) 2007-03-28
KR101274867B1 (ko) 2013-06-13
BRPI0409387B1 (pt) 2021-05-11
HK1094150A1 (zh) 2007-03-23
AU2004229218B2 (en) 2009-05-07
JP2006523664A (ja) 2006-10-19
KR20060015507A (ko) 2006-02-17
BRPI0409387B8 (pt) 2021-05-25
JP5468597B2 (ja) 2014-04-09
MXPA05010804A (es) 2006-03-09
CY1115407T1 (el) 2017-01-04
JP2012051942A (ja) 2012-03-15
ES2486845T3 (es) 2014-08-19
EP1617876B1 (en) 2014-05-14
EA200501456A1 (ru) 2006-06-30
NO332931B1 (no) 2013-02-04
DK1617876T3 (da) 2014-07-21
NO20055390D0 (no) 2005-11-15
CA2522148C (en) 2010-07-13
PT1617876E (pt) 2014-08-04
EA008195B1 (ru) 2007-04-27
NZ606996A (en) 2014-08-29
NZ595758A (en) 2013-02-22
KR20110022743A (ko) 2011-03-07
AU2004229218A1 (en) 2004-10-28
EP1617876A1 (en) 2006-01-25
IL171148A (en) 2013-12-31
BRPI0409387A (pt) 2006-04-18
NO20055390L (no) 2006-01-16
CA2522148A1 (en) 2004-10-28
CN1805760A (zh) 2006-07-19
PL1617876T3 (pl) 2015-03-31
CN100586484C (zh) 2010-02-03
NZ543044A (en) 2010-04-30

Similar Documents

Publication Publication Date Title
JP5468597B2 (ja) 軟組織疾患の放射線治療におけるトリウム−２２７を用いた医薬組成物、複合体及びその調製方法、並びにキット
US20140235924A1 (en) Method of radiotherapy
JP7376481B2 (ja) 鉛またはトリウム放射性核種に連結されたｐｓｍａ標的化化合物を含む錯体
Miederer et al. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications
A Scheinberg et al. Actinium-225 in targeted alpha-particle therapeutic applications
AU2005259258B2 (en) Radionuclides for medical use
Huclier-Markai et al. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics
CZ299087B6 (cs) Farmaceutický prostredek
RU2741794C2 (ru) Радиофармацевтические растворы с предпочтительными свойствами
US20060228297A1 (en) Thorium-227 for use in radiotherapy of soft tissue disease
US7794691B2 (en) Radionuclides for medical use
Bruland et al. Radium-223: From radiochemical development to clinical applications in targeted cancer therapy
CA3121553A1 (en) Antibodies conjugated with actinium-225 and actinium-227, and related compositions and methods
Govindan et al. Advances in the use of monoclonal antibodies in cancer radiotherapy
Sowa Dumond et al. Concepts and issues for therapeutic radiopharmaceuticals
HK1094150B (en) Thorium-227 for use in radiotherapy of soft tissue disease
RU2795398C2 (ru) Комплекс, содержащий нацеливающееся на psma соединение, связанное с радионуклидом свинца или тория
Bailey Advancing targeting radiopharmaceuticals for theranostic applications

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100318

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110802

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120126

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120424

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120524

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150601

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5006032

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term